N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=81 Medications for Stopping Cocaine Dependence and Preventing Relapse
Cocaine Abuse · Cocaine-Related Disorders
Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 2 N=150 Gabapentin Treatment of Alcohol Dependence
Alcoholism · Alcohol Dependence
Primary: Drinking — 6; 8; 2 participants — p=<0.04
Phase 2 N=31 Carvedilol for Psychostimulant Dependence
Cocaine Dependence · Cocaine Withdrawal
Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05
Phase 2 N=108 New Medication Treatment for Stimulant Dependence
Cocaine Dependence
Primary: Cocaine Use by Self-report — 67; 67 Percent of cocaine-free (abstinent)days — p=0.972
Phase 2 N=66 Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
Cannabis Dependence · Cannabis Withdrawal
Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…
Phase 2 N=27 D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals
Cocaine Use Disorders
Primary: Cocaine Craving Scale — 4.33; 3.13 Units on a scale
Phase 3 N=123 A Physical Dependence Study in Schizophrenia
Schizophrenia
Primary: Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score — 13.23; 11.50 units on a scale — p=0.170
Phase 2 N=80 VIVITROL as a Treatment for Cocaine and Alcohol Dependence
Cocaine Dependence · Alcohol Dependence
Primary: Urine Assay for Benzoylecgonine (BE), the Primary Metabolite of Cocaine. — 33.3; 31.7 Percentage of Participants
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
N/A N=321 Effectiveness of Extended Treatments for Drug Dependence
Cocaine Dependence
Primary: Abstinence — 45; 57; 45 participants
Phase 2 N=15 Study of Quetiapine Treatment for Cannabis Dependence
Cannabis Dependence
Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams
Phase 2 N=50 Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
Substance Abuse
Primary: % Urine Samples Negative for Cocaine — .67; .74 percentage of positive urine samples
N/A N=667 LINK: Aftercare Monitoring Project
Alcohol Dependence · Drug Dependence
Primary: Rates of Substance Use — 91.1; 88.0 percentage of days
Phase 2 N=150 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence · Cannabis Withdrawal · Cognitive Deficits
Primary: Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period — 11.22…
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
Phase 2 N=50 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029
Phase 2 N=138 Neural Substrates of Emotion: Impact of Cocaine Dependence
Cocaine Use Disorder
Primary: Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress — .011; .012; .043; .0008 Arbitrary units
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=330 The Effect of a Contingency Management Intervention on Substance Use
Substance Use Disorders
Primary: Number of Negative Breath Alcohol and Urine Drug Screens Out of Possible 16 — 11.93; 10.39 negative alcohol and drug screens — p=<.001
N/A N=2,057 The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…
Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
Phase 2 N=118 Disulfiram for Cocaine Abuse
Cocaine Dependence
Primary: Cocaine Use Over Time — 0.01; 0.007; -0.01; 0.007 slope (change in prob of coc-pos utox/d) — p=<0.05
N/A N=368 Feasibility and Validation of a Standard Phenotyping Assessment Battery
Opioid-use Disorder · Cocaine Use Disorder · Marijuana Use Disorder
Primary: Retention — 4; 27; 10; 21 Participants
N/A N=345 Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)
Opioid-Related Disorders · Opiate Dependence · Drug Abuse
Primary: Retention Rate After 12 Months of Treatment With Suboxone — 59.9 % of participants
Phase 2 N=130 Quetiapine Pharmacotherapy for Cannabis Dependence
Cannabis Dependence
Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars